Piper Sandler analyst Yasmeen Rahimi downgraded Prometheus (RXDX) to Neutral from Overweight with a price target of $200, up from $138, after Merck (MRK) announced plans to acquire the company for $10.8B in cash, or $200 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXDX: